Goldman Sachs is one of the biggest investment banker “book runners” for IPOs -- where banks are paid many millions of ...

Analysts from Wolfe Research, Goldman Sachs, and HSBC downgrade AMD, citing weak AI chip demand and rising competition. Could ...

Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

Goldman Sachs has flagged Insmed Inc. as a potential merger candidate under the pro-business policies of the incoming Donald ...

Goldman Sachs is seeking to end its Apple Card partnership with Apply before their contract expires.